European journal of clinical investigation
-
Eur. J. Clin. Invest. · Apr 2021
Review Meta AnalysisEffect of low-dose colchicine in acute and chronic coronary syndromes.
Sparse evidence of the prognostic benefit of the anti-inflammatory drug colchicine in chronic and acute coronary syndromes (CCS/ACS) exists. ⋯ Colchicine therapy near halves the risk of cardiovascular events in CCS compared with placebo and is associated with a nonsignificant 23% risk reduction in ACS, together with a trend towards a greater reduction of hs-CRP.